Global Antisense Oligonucleotides Drugs for ATTR Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Antisense Oligonucleotides Drugs for ATTR Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 74

Published Date: 13 Aug 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

  • sp_icon1 sp_icon1_b Description
  • sp_icon2 sp_icon2_b Table of Contents
  • sp_icon3 sp_icon3_b Table of Figures
  • sp_icon4 sp_icon4_b Research Methodology
  • sp_icon1 sp_icon1_b Companies Mentioned
  • sp_icon1 sp_icon1_b Related Reports
  • sp_icon1 sp_icon1_b Product Tags
btl

Description

Antisense oligonucleotide(ASO)drugs represent a groundbreaking approach for treating transthyretin amyloidosis(ATTR),a condition characterized by the accumulation of misfolded transthyretin proteins that lead to organ damage.These ASO drugs work by targeting and degrading the mRNA that encodes for transthyretin,thus reducing its production at the source.

According to our (Global Info Research) latest study, the global Antisense Oligonucleotides Drugs for ATTR market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

This report is a detailed and comprehensive analysis for global Antisense Oligonucleotides Drugs for ATTR market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Antisense Oligonucleotides Drugs for ATTR market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Antisense Oligonucleotides Drugs for ATTR market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Antisense Oligonucleotides Drugs for ATTR market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Antisense Oligonucleotides Drugs for ATTR market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Antisense Oligonucleotides Drugs for ATTR
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Antisense Oligonucleotides Drugs for ATTR market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Akcea Therapeutics, AstraZeneca, Ionis Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Antisense Oligonucleotides Drugs for ATTR market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Inotersen
Eplontersen
Other

Market segment by Application
Hospital and Clinic
Retail Pharmacies
Other

Major players covered
Akcea Therapeutics
AstraZeneca
Ionis Pharmaceuticals

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antisense Oligonucleotides Drugs for ATTR product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Antisense Oligonucleotides Drugs for ATTR, with price, sales quantity, revenue, and global market share of Antisense Oligonucleotides Drugs for ATTR from 2019 to 2024.
Chapter 3, the Antisense Oligonucleotides Drugs for ATTR competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antisense Oligonucleotides Drugs for ATTR breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Antisense Oligonucleotides Drugs for ATTR market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Antisense Oligonucleotides Drugs for ATTR.
Chapter 14 and 15, to describe Antisense Oligonucleotides Drugs for ATTR sales channel, distributors, customers, research findings and conclusion.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Inotersen
1.3.3 Eplontersen
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital and Clinic
1.4.3 Retail Pharmacies
1.4.4 Other
1.5 Global Antisense Oligonucleotides Drugs for ATTR Market Size & Forecast
1.5.1 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity (2019-2030)
1.5.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price (2019-2030)

2 Manufacturers Profiles
2.1 Akcea Therapeutics
2.1.1 Akcea Therapeutics Details
2.1.2 Akcea Therapeutics Major Business
2.1.3 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Product and Services
2.1.4 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Akcea Therapeutics Recent Developments/Updates
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Product and Services
2.2.4 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 AstraZeneca Recent Developments/Updates
2.3 Ionis Pharmaceuticals
2.3.1 Ionis Pharmaceuticals Details
2.3.2 Ionis Pharmaceuticals Major Business
2.3.3 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Product and Services
2.3.4 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Ionis Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Antisense Oligonucleotides Drugs for ATTR by Manufacturer
3.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Manufacturer (2019-2024)
3.2 Global Antisense Oligonucleotides Drugs for ATTR Revenue by Manufacturer (2019-2024)
3.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Antisense Oligonucleotides Drugs for ATTR by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Antisense Oligonucleotides Drugs for ATTR Manufacturer Market Share in 2023
3.4.3 Top 6 Antisense Oligonucleotides Drugs for ATTR Manufacturer Market Share in 2023
3.5 Antisense Oligonucleotides Drugs for ATTR Market: Overall Company Footprint Analysis
3.5.1 Antisense Oligonucleotides Drugs for ATTR Market: Region Footprint
3.5.2 Antisense Oligonucleotides Drugs for ATTR Market: Company Product Type Footprint
3.5.3 Antisense Oligonucleotides Drugs for ATTR Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
4.1 Global Antisense Oligonucleotides Drugs for ATTR Market Size by Region
4.1.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2019-2030)
4.1.2 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2030)
4.1.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Region (2019-2030)
4.2 North America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)
4.3 Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)
4.4 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)
4.5 South America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)
4.6 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)

5 Market Segment by Type
5.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
5.2 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type (2019-2030)
5.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Type (2019-2030)

6 Market Segment by Application
6.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
6.2 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application (2019-2030)
6.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Application (2019-2030)

7 North America
7.1 North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
7.2 North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
7.3 North America Antisense Oligonucleotides Drugs for ATTR Market Size by Country
7.3.1 North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2030)
7.3.2 North America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
8.1 Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
8.2 Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
8.3 Europe Antisense Oligonucleotides Drugs for ATTR Market Size by Country
8.3.1 Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2030)
8.3.2 Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
9.1 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Market Size by Region
9.3.1 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 South Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
10.1 South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
10.2 South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
10.3 South America Antisense Oligonucleotides Drugs for ATTR Market Size by Country
10.3.1 South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2030)
10.3.2 South America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
11.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Market Size by Country
11.3.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
12.1 Antisense Oligonucleotides Drugs for ATTR Market Drivers
12.2 Antisense Oligonucleotides Drugs for ATTR Market Restraints
12.3 Antisense Oligonucleotides Drugs for ATTR Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
13.1 Raw Material of Antisense Oligonucleotides Drugs for ATTR and Key Manufacturers
13.2 Manufacturing Costs Percentage of Antisense Oligonucleotides Drugs for ATTR
13.3 Antisense Oligonucleotides Drugs for ATTR Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Antisense Oligonucleotides Drugs for ATTR Typical Distributors
14.3 Antisense Oligonucleotides Drugs for ATTR Typical Customers

15 Research Findings and Conclusion

16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Akcea Therapeutics Basic Information, Manufacturing Base and Competitors
Table 4. Akcea Therapeutics Major Business
Table 5. Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Product and Services
Table 6. Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Akcea Therapeutics Recent Developments/Updates
Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 9. AstraZeneca Major Business
Table 10. AstraZeneca Antisense Oligonucleotides Drugs for ATTR Product and Services
Table 11. AstraZeneca Antisense Oligonucleotides Drugs for ATTR Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. AstraZeneca Recent Developments/Updates
Table 13. Ionis Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. Ionis Pharmaceuticals Major Business
Table 15. Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Product and Services
Table 16. Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Ionis Pharmaceuticals Recent Developments/Updates
Table 18. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 19. Global Antisense Oligonucleotides Drugs for ATTR Revenue by Manufacturer (2019-2024) & (USD Million)
Table 20. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 21. Market Position of Manufacturers in Antisense Oligonucleotides Drugs for ATTR, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 22. Head Office and Antisense Oligonucleotides Drugs for ATTR Production Site of Key Manufacturer
Table 23. Antisense Oligonucleotides Drugs for ATTR Market: Company Product Type Footprint
Table 24. Antisense Oligonucleotides Drugs for ATTR Market: Company Product Application Footprint
Table 25. Antisense Oligonucleotides Drugs for ATTR New Market Entrants and Barriers to Market Entry
Table 26. Antisense Oligonucleotides Drugs for ATTR Mergers, Acquisition, Agreements, and Collaborations
Table 27. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
Table 28. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2019-2024) & (K Units)
Table 29. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2025-2030) & (K Units)
Table 30. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2024) & (USD Million)
Table 31. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2025-2030) & (USD Million)
Table 32. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Region (2019-2024) & (US$/Unit)
Table 33. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Region (2025-2030) & (US$/Unit)
Table 34. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 35. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 36. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type (2019-2024) & (USD Million)
Table 37. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type (2025-2030) & (USD Million)
Table 38. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Type (2019-2024) & (US$/Unit)
Table 39. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Type (2025-2030) & (US$/Unit)
Table 40. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 41. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 42. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application (2019-2024) & (USD Million)
Table 43. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application (2025-2030) & (USD Million)
Table 44. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Application (2019-2024) & (US$/Unit)
Table 45. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Application (2025-2030) & (US$/Unit)
Table 46. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 47. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 48. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 49. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 50. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2024) & (K Units)
Table 51. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2025-2030) & (K Units)
Table 52. North America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2024) & (USD Million)
Table 53. North America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2025-2030) & (USD Million)
Table 54. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 55. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 56. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 57. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 58. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2024) & (K Units)
Table 59. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2025-2030) & (K Units)
Table 60. Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2024) & (USD Million)
Table 61. Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2025-2030) & (USD Million)
Table 62. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 63. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 64. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 65. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 66. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2019-2024) & (K Units)
Table 67. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2025-2030) & (K Units)
Table 68. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2024) & (USD Million)
Table 69. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2025-2030) & (USD Million)
Table 70. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 71. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 72. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 73. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 74. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2024) & (K Units)
Table 75. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2025-2030) & (K Units)
Table 76. South America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2024) & (USD Million)
Table 77. South America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2025-2030) & (USD Million)
Table 78. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 79. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 80. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 81. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 82. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2024) & (K Units)
Table 83. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2025-2030) & (K Units)
Table 84. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Antisense Oligonucleotides Drugs for ATTR Raw Material
Table 87. Key Manufacturers of Antisense Oligonucleotides Drugs for ATTR Raw Materials
Table 88. Antisense Oligonucleotides Drugs for ATTR Typical Distributors
Table 89. Antisense Oligonucleotides Drugs for ATTR Typical Customers


List of Figures
Figure 1. Antisense Oligonucleotides Drugs for ATTR Picture
Figure 2. Global Antisense Oligonucleotides Drugs for ATTR Revenue by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Type in 2023
Figure 4. Inotersen Examples
Figure 5. Eplontersen Examples
Figure 6. Other Examples
Figure 7. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Application in 2023
Figure 9. Hospital and Clinic Examples
Figure 10. Retail Pharmacies Examples
Figure 11. Other Examples
Figure 12. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity (2019-2030) & (K Units)
Figure 15. Global Antisense Oligonucleotides Drugs for ATTR Price (2019-2030) & (US$/Unit)
Figure 16. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Manufacturer in 2023
Figure 17. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Manufacturer in 2023
Figure 18. Producer Shipments of Antisense Oligonucleotides Drugs for ATTR by Manufacturer Sales ($MM) and Market Share (%): 2023
Figure 19. Top 3 Antisense Oligonucleotides Drugs for ATTR Manufacturer (Revenue) Market Share in 2023
Figure 20. Top 6 Antisense Oligonucleotides Drugs for ATTR Manufacturer (Revenue) Market Share in 2023
Figure 21. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Region (2019-2030)
Figure 22. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Region (2019-2030)
Figure 23. North America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 24. Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 25. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 26. South America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 27. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 28. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 29. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Type (2019-2030)
Figure 30. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Type (2019-2030) & (US$/Unit)
Figure 31. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 32. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Application (2019-2030)
Figure 33. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Application (2019-2030) & (US$/Unit)
Figure 34. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 35. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 36. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Country (2019-2030)
Figure 37. North America Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Country (2019-2030)
Figure 38. United States Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 39. Canada Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 40. Mexico Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 41. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 42. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 43. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Country (2019-2030)
Figure 44. Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Country (2019-2030)
Figure 45. Germany Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 46. France Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 47. United Kingdom Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 48. Russia Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 49. Italy Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 50. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 51. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 52. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Region (2019-2030)
Figure 53. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Region (2019-2030)
Figure 54. China Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 55. Japan Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 56. South Korea Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 57. India Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 58. Southeast Asia Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 59. Australia Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 60. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 61. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 62. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Country (2019-2030)
Figure 63. South America Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Country (2019-2030)
Figure 64. Brazil Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 65. Argentina Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 66. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 67. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 68. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Country (2019-2030)
Figure 69. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Country (2019-2030)
Figure 70. Turkey Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 71. Egypt Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 72. Saudi Arabia Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 73. South Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 74. Antisense Oligonucleotides Drugs for ATTR Market Drivers
Figure 75. Antisense Oligonucleotides Drugs for ATTR Market Restraints
Figure 76. Antisense Oligonucleotides Drugs for ATTR Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Antisense Oligonucleotides Drugs for ATTR in 2023
Figure 79. Manufacturing Process Analysis of Antisense Oligonucleotides Drugs for ATTR
Figure 80. Antisense Oligonucleotides Drugs for ATTR Industrial Chain
Figure 81. Sales Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Akcea Therapeutics
AstraZeneca
Ionis Pharmaceuticals
shop_t

Purchase Options

jiaGou

Add To Cart

jiaGou

Buy Now

masterCard
visa
jcb
americanExpress
shop_b
Global Antisense Oligonucleotides Drugs for ATTR Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Antisense Oligonucleotides Drugs for ATTR Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 74

Published Date: 13 Aug 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description

arrow-d3
btl

Description

Antisense oligonucleotide(ASO)drugs represent a groundbreaking approach for treating transthyretin amyloidosis(ATTR),a condition characterized by the accumulation of misfolded transthyretin proteins that lead to organ damage.These ASO drugs work by targeting and degrading the mRNA that encodes for transthyretin,thus reducing its production at the source.

According to our (Global Info Research) latest study, the global Antisense Oligonucleotides Drugs for ATTR market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

This report is a detailed and comprehensive analysis for global Antisense Oligonucleotides Drugs for ATTR market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Antisense Oligonucleotides Drugs for ATTR market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Antisense Oligonucleotides Drugs for ATTR market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Antisense Oligonucleotides Drugs for ATTR market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Antisense Oligonucleotides Drugs for ATTR market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Antisense Oligonucleotides Drugs for ATTR
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Antisense Oligonucleotides Drugs for ATTR market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Akcea Therapeutics, AstraZeneca, Ionis Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Antisense Oligonucleotides Drugs for ATTR market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Inotersen
Eplontersen
Other

Market segment by Application
Hospital and Clinic
Retail Pharmacies
Other

Major players covered
Akcea Therapeutics
AstraZeneca
Ionis Pharmaceuticals

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antisense Oligonucleotides Drugs for ATTR product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Antisense Oligonucleotides Drugs for ATTR, with price, sales quantity, revenue, and global market share of Antisense Oligonucleotides Drugs for ATTR from 2019 to 2024.
Chapter 3, the Antisense Oligonucleotides Drugs for ATTR competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antisense Oligonucleotides Drugs for ATTR breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Antisense Oligonucleotides Drugs for ATTR market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Antisense Oligonucleotides Drugs for ATTR.
Chapter 14 and 15, to describe Antisense Oligonucleotides Drugs for ATTR sales channel, distributors, customers, research findings and conclusion.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Inotersen
1.3.3 Eplontersen
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital and Clinic
1.4.3 Retail Pharmacies
1.4.4 Other
1.5 Global Antisense Oligonucleotides Drugs for ATTR Market Size & Forecast
1.5.1 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity (2019-2030)
1.5.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price (2019-2030)

2 Manufacturers Profiles
2.1 Akcea Therapeutics
2.1.1 Akcea Therapeutics Details
2.1.2 Akcea Therapeutics Major Business
2.1.3 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Product and Services
2.1.4 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Akcea Therapeutics Recent Developments/Updates
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Product and Services
2.2.4 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 AstraZeneca Recent Developments/Updates
2.3 Ionis Pharmaceuticals
2.3.1 Ionis Pharmaceuticals Details
2.3.2 Ionis Pharmaceuticals Major Business
2.3.3 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Product and Services
2.3.4 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Ionis Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Antisense Oligonucleotides Drugs for ATTR by Manufacturer
3.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Manufacturer (2019-2024)
3.2 Global Antisense Oligonucleotides Drugs for ATTR Revenue by Manufacturer (2019-2024)
3.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Antisense Oligonucleotides Drugs for ATTR by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Antisense Oligonucleotides Drugs for ATTR Manufacturer Market Share in 2023
3.4.3 Top 6 Antisense Oligonucleotides Drugs for ATTR Manufacturer Market Share in 2023
3.5 Antisense Oligonucleotides Drugs for ATTR Market: Overall Company Footprint Analysis
3.5.1 Antisense Oligonucleotides Drugs for ATTR Market: Region Footprint
3.5.2 Antisense Oligonucleotides Drugs for ATTR Market: Company Product Type Footprint
3.5.3 Antisense Oligonucleotides Drugs for ATTR Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
4.1 Global Antisense Oligonucleotides Drugs for ATTR Market Size by Region
4.1.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2019-2030)
4.1.2 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2030)
4.1.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Region (2019-2030)
4.2 North America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)
4.3 Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)
4.4 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)
4.5 South America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)
4.6 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030)

5 Market Segment by Type
5.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
5.2 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type (2019-2030)
5.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Type (2019-2030)

6 Market Segment by Application
6.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
6.2 Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application (2019-2030)
6.3 Global Antisense Oligonucleotides Drugs for ATTR Average Price by Application (2019-2030)

7 North America
7.1 North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
7.2 North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
7.3 North America Antisense Oligonucleotides Drugs for ATTR Market Size by Country
7.3.1 North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2030)
7.3.2 North America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
8.1 Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
8.2 Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
8.3 Europe Antisense Oligonucleotides Drugs for ATTR Market Size by Country
8.3.1 Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2030)
8.3.2 Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
9.1 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Market Size by Region
9.3.1 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 South Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
10.1 South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
10.2 South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
10.3 South America Antisense Oligonucleotides Drugs for ATTR Market Size by Country
10.3.1 South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2030)
10.3.2 South America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
11.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Market Size by Country
11.3.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
12.1 Antisense Oligonucleotides Drugs for ATTR Market Drivers
12.2 Antisense Oligonucleotides Drugs for ATTR Market Restraints
12.3 Antisense Oligonucleotides Drugs for ATTR Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
13.1 Raw Material of Antisense Oligonucleotides Drugs for ATTR and Key Manufacturers
13.2 Manufacturing Costs Percentage of Antisense Oligonucleotides Drugs for ATTR
13.3 Antisense Oligonucleotides Drugs for ATTR Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Antisense Oligonucleotides Drugs for ATTR Typical Distributors
14.3 Antisense Oligonucleotides Drugs for ATTR Typical Customers

15 Research Findings and Conclusion

16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Akcea Therapeutics Basic Information, Manufacturing Base and Competitors
Table 4. Akcea Therapeutics Major Business
Table 5. Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Product and Services
Table 6. Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Akcea Therapeutics Recent Developments/Updates
Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 9. AstraZeneca Major Business
Table 10. AstraZeneca Antisense Oligonucleotides Drugs for ATTR Product and Services
Table 11. AstraZeneca Antisense Oligonucleotides Drugs for ATTR Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. AstraZeneca Recent Developments/Updates
Table 13. Ionis Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. Ionis Pharmaceuticals Major Business
Table 15. Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Product and Services
Table 16. Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Ionis Pharmaceuticals Recent Developments/Updates
Table 18. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 19. Global Antisense Oligonucleotides Drugs for ATTR Revenue by Manufacturer (2019-2024) & (USD Million)
Table 20. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 21. Market Position of Manufacturers in Antisense Oligonucleotides Drugs for ATTR, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 22. Head Office and Antisense Oligonucleotides Drugs for ATTR Production Site of Key Manufacturer
Table 23. Antisense Oligonucleotides Drugs for ATTR Market: Company Product Type Footprint
Table 24. Antisense Oligonucleotides Drugs for ATTR Market: Company Product Application Footprint
Table 25. Antisense Oligonucleotides Drugs for ATTR New Market Entrants and Barriers to Market Entry
Table 26. Antisense Oligonucleotides Drugs for ATTR Mergers, Acquisition, Agreements, and Collaborations
Table 27. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
Table 28. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2019-2024) & (K Units)
Table 29. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2025-2030) & (K Units)
Table 30. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2024) & (USD Million)
Table 31. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2025-2030) & (USD Million)
Table 32. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Region (2019-2024) & (US$/Unit)
Table 33. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Region (2025-2030) & (US$/Unit)
Table 34. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 35. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 36. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type (2019-2024) & (USD Million)
Table 37. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Type (2025-2030) & (USD Million)
Table 38. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Type (2019-2024) & (US$/Unit)
Table 39. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Type (2025-2030) & (US$/Unit)
Table 40. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 41. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 42. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application (2019-2024) & (USD Million)
Table 43. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application (2025-2030) & (USD Million)
Table 44. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Application (2019-2024) & (US$/Unit)
Table 45. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Application (2025-2030) & (US$/Unit)
Table 46. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 47. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 48. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 49. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 50. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2024) & (K Units)
Table 51. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2025-2030) & (K Units)
Table 52. North America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2024) & (USD Million)
Table 53. North America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2025-2030) & (USD Million)
Table 54. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 55. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 56. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 57. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 58. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2024) & (K Units)
Table 59. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2025-2030) & (K Units)
Table 60. Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2024) & (USD Million)
Table 61. Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2025-2030) & (USD Million)
Table 62. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 63. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 64. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 65. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 66. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2019-2024) & (K Units)
Table 67. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Region (2025-2030) & (K Units)
Table 68. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2019-2024) & (USD Million)
Table 69. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value by Region (2025-2030) & (USD Million)
Table 70. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 71. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 72. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 73. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 74. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2024) & (K Units)
Table 75. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2025-2030) & (K Units)
Table 76. South America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2024) & (USD Million)
Table 77. South America Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2025-2030) & (USD Million)
Table 78. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2019-2024) & (K Units)
Table 79. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Type (2025-2030) & (K Units)
Table 80. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2019-2024) & (K Units)
Table 81. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Application (2025-2030) & (K Units)
Table 82. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2019-2024) & (K Units)
Table 83. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity by Country (2025-2030) & (K Units)
Table 84. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Antisense Oligonucleotides Drugs for ATTR Raw Material
Table 87. Key Manufacturers of Antisense Oligonucleotides Drugs for ATTR Raw Materials
Table 88. Antisense Oligonucleotides Drugs for ATTR Typical Distributors
Table 89. Antisense Oligonucleotides Drugs for ATTR Typical Customers


List of Figures
Figure 1. Antisense Oligonucleotides Drugs for ATTR Picture
Figure 2. Global Antisense Oligonucleotides Drugs for ATTR Revenue by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Type in 2023
Figure 4. Inotersen Examples
Figure 5. Eplontersen Examples
Figure 6. Other Examples
Figure 7. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Application in 2023
Figure 9. Hospital and Clinic Examples
Figure 10. Retail Pharmacies Examples
Figure 11. Other Examples
Figure 12. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity (2019-2030) & (K Units)
Figure 15. Global Antisense Oligonucleotides Drugs for ATTR Price (2019-2030) & (US$/Unit)
Figure 16. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Manufacturer in 2023
Figure 17. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Manufacturer in 2023
Figure 18. Producer Shipments of Antisense Oligonucleotides Drugs for ATTR by Manufacturer Sales ($MM) and Market Share (%): 2023
Figure 19. Top 3 Antisense Oligonucleotides Drugs for ATTR Manufacturer (Revenue) Market Share in 2023
Figure 20. Top 6 Antisense Oligonucleotides Drugs for ATTR Manufacturer (Revenue) Market Share in 2023
Figure 21. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Region (2019-2030)
Figure 22. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Region (2019-2030)
Figure 23. North America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 24. Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 25. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 26. South America Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 27. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 28. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 29. Global Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Type (2019-2030)
Figure 30. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Type (2019-2030) & (US$/Unit)
Figure 31. Global Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 32. Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Application (2019-2030)
Figure 33. Global Antisense Oligonucleotides Drugs for ATTR Average Price by Application (2019-2030) & (US$/Unit)
Figure 34. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 35. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 36. North America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Country (2019-2030)
Figure 37. North America Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Country (2019-2030)
Figure 38. United States Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 39. Canada Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 40. Mexico Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 41. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 42. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 43. Europe Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Country (2019-2030)
Figure 44. Europe Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Country (2019-2030)
Figure 45. Germany Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 46. France Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 47. United Kingdom Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 48. Russia Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 49. Italy Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 50. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 51. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 52. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Region (2019-2030)
Figure 53. Asia-Pacific Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Region (2019-2030)
Figure 54. China Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 55. Japan Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 56. South Korea Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 57. India Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 58. Southeast Asia Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 59. Australia Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 60. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 61. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 62. South America Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Country (2019-2030)
Figure 63. South America Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Country (2019-2030)
Figure 64. Brazil Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 65. Argentina Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 66. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Type (2019-2030)
Figure 67. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Application (2019-2030)
Figure 68. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Quantity Market Share by Country (2019-2030)
Figure 69. Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value Market Share by Country (2019-2030)
Figure 70. Turkey Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 71. Egypt Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 72. Saudi Arabia Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 73. South Africa Antisense Oligonucleotides Drugs for ATTR Consumption Value (2019-2030) & (USD Million)
Figure 74. Antisense Oligonucleotides Drugs for ATTR Market Drivers
Figure 75. Antisense Oligonucleotides Drugs for ATTR Market Restraints
Figure 76. Antisense Oligonucleotides Drugs for ATTR Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Antisense Oligonucleotides Drugs for ATTR in 2023
Figure 79. Manufacturing Process Analysis of Antisense Oligonucleotides Drugs for ATTR
Figure 80. Antisense Oligonucleotides Drugs for ATTR Industrial Chain
Figure 81. Sales Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Discussion of all the project requirements and queries

Validation and triangulation of secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Akcea Therapeutics
AstraZeneca
Ionis Pharmaceuticals
jiaGou

Add To Cart

gouMai

Buy Now